Peptides Under Investigation in Women’s Hormonal and Aging Research: A Perimenopausal Context

For research purposes only. Not for human consumption.

Women’s hormonal aging research has expanded significantly in the last decade. The perimenopause window — typically spanning the late 30s through mid-50s — involves a complex interplay of hormonal fluctuation, metabolic shift, inflammatory activity, and tissue remodeling that researchers across endocrinology, gerontology, and peptide biology are increasingly interested in studying.

This post covers five peptides from the research literature that have been investigated in contexts relevant to hormonal aging, metabolic regulation, and the biological processes that characterize this transition period. This is an emerging research area — findings are preliminary, largely preclinical, and should not be interpreted as medical guidance.

Epitalon: Pineal Regulation and Hormonal Rhythm Research

Epitalon (Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary research focus has been pineal gland function, specifically the regulation of melatonin secretion and the hypothalamic-pituitary axis.

The pineal gland’s role in reproductive aging is well-documented in the literature. Melatonin — whose synthesis the pineal gland controls — declines with age, and this decline correlates with disruption of circadian hormonal cycles including LH, FSH, and estrogen pulsatility. In rodent models, Epitalon administration has been associated with prolonged estrous cyclicity and preserved reproductive function in aged animals.

Researchers studying the aging hypothalamic-pituitary-gonadal (HPG) axis have also examined Epitalon for its apparent influence on telomerase activity — a mechanism through which it may intersect with cellular aging processes in hormone-producing tissues.

→ View Epitalon in the research catalog

GHK-Cu: Collagen Synthesis, Skin Integrity, and Anti-Inflammatory Research

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a naturally occurring tripeptide that was first isolated from human plasma and has since been studied extensively for its role in tissue remodeling and wound healing.

In the context of women’s aging research, GHK-Cu is relevant at multiple levels. Estrogen plays a central role in maintaining collagen density — estrogen deficiency following perimenopause is associated with significant decreases in skin collagen content. GHK-Cu research has demonstrated stimulation of collagen I and III synthesis in fibroblast models, upregulation of elastin and proteoglycan production, and modulation of TGF-β signaling.

Beyond the dermis, GHK-Cu has also been studied for systemic anti-inflammatory properties. The perimenopausal transition is associated with an elevation of inflammatory biomarkers — a phenomenon sometimes called “inflammaging” — and peptides with anti-inflammatory research profiles are a logical area of interest in this context.

Loren Pickart’s foundational research on GHK-Cu established its role as a biological signal for tissue regeneration and repair — a mechanism that researchers continue to explore across aging tissue types.

→ View GHK-Cu in the research catalog

MOTS-c: Mitochondrial Peptide and Metabolic Regulation Research

MOTS-c is a mitochondria-derived peptide encoded within the mitochondrial 12S rRNA gene. It was first characterized by Lee et al. (2015) in Cell Metabolism, making it one of the more recently discovered peptides in the field.

MOTS-c research has centered on metabolic regulation — specifically, its apparent role in glucose uptake, insulin sensitivity, and lipid metabolism in skeletal muscle. Animal studies have shown MOTS-c administration reduces adiposity and improves insulin signaling, particularly under conditions of dietary stress.

The relevance to perimenopausal biology is direct: the metabolic shift that accompanies estrogen decline — including increased central adiposity, insulin resistance, and reduced mitochondrial efficiency in muscle — maps closely to the pathways MOTS-c appears to influence in preclinical models. Some researchers have hypothesized a relationship between declining MOTS-c levels and age-related metabolic decline, though this remains speculative without human longitudinal data.

→ View MOTS-c in the research catalog

Tesamorelin: GHRH Analog and Growth Hormone Research

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the endogenous signal that triggers GH secretion from the pituitary. Unlike direct GH administration, Tesamorelin stimulates physiological pulsatile GH release, which researchers consider a more biomimetic approach.

Growth hormone secretion declines with age in both sexes, but the rate of this decline — particularly in conjunction with estrogen loss — creates a distinct research interest in the perimenopausal context. GH influences body composition (lean mass maintenance, visceral fat metabolism), bone mineral density, and various aspects of metabolic function.

Tesamorelin has FDA approval for HIV-associated lipodystrophy (a specific body composition disorder), making it one of the better-characterized compounds in the GHRH analog class. Research outside that indication is ongoing — body composition and metabolic outcomes in aging populations are an active area of investigation.

→ View Tesamorelin in the research catalog

BPC-157: Systemic Anti-Inflammatory and Tissue Repair Research

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a sequence in human gastric juice. Its preclinical research profile is among the broadest of any peptide currently under active study, spanning gastrointestinal integrity, tendon and ligament repair, and systemic anti-inflammatory effects.

In the context of women’s aging research, BPC-157’s relevance lies primarily in its anti-inflammatory profile. Musculoskeletal vulnerability increases during perimenopause — connective tissue laxity, joint inflammation, and changes in tendon composition are well-documented correlates of estrogen decline. BPC-157’s activity on nitric oxide pathways, growth factor expression, and inflammatory cytokine modulation has been studied across multiple tissue types in animal models.

Additionally, BPC-157’s apparent stabilizing effect on the gut-brain axis is of interest to researchers studying the bidirectional relationship between gut health and hormonal signaling — a relationship that several research groups are actively characterizing.

→ View BPC-157 10mg in the research catalog

A Note on Where This Research Stands

The peptide research described in this post spans multiple decades and multiple research groups. Some findings — particularly Epitalon and GHK-Cu — have a substantial literature base. Others, like MOTS-c, are more recent and have a smaller evidence base to draw from.

None of these compounds have been studied in clinical trials specifically for perimenopausal indications. Extrapolation from preclinical models to human hormonal biology requires significant caution. Researchers in this space are encouraged to approach the literature critically and design protocols that acknowledge the current evidence gaps.

This is an early-stage but genuinely interesting area of peptide science — one we’ll continue to cover as the literature develops.

Explore our full research catalog at Alpha Peptides US — third-party tested, COAs published for every product.

→ Shop Epitalon · Shop GHK-Cu · Shop MOTS-c · Shop Tesamorelin · Shop BPC-157

All products are for research purposes only. Not for human consumption.

References (Research Basis)

• Khavinson VKh, et al. “Peptide regulation of aging.” Bulletin of Experimental Biology and Medicine. 2003.
• Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Aging.” BioMed Research International. 2015.
• Lee C, et al. “The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance.” Cell Metabolism. 2015.
• Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007.
• Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current Neuropharmacology. 2016.
• Stevenson JC. “Hormone replacement therapy and cardiovascular disease revisited.” Menopause International. 2009. (Background reference on estrogen/collagen relationship.)